Efremidis Michael, Bazoukis George, Vlachos Konstantinos, Prappa Efstathia, Megarisiotou Athanasia, Dragasis Stylianos, Ramirez F Daniel, Bourier Felix, Mililis Panagiotis, Saplaouras Athanasios, Tse Gary, Liu Tong, Efremidis Theodore, Kitsoulis Panagiotis, Thomopoulos Costas, Sideris Antonios, Letsas Konstantinos P
Second Department of Cardiology Laboratory of Cardiac Electrophysiology "Evangelismos" General Hospital of Athens Athens Greece.
Hôpital Cardiologique du Haut Lévèque CHU de Bordeaux and IHU-LIRYC Pessac France.
J Arrhythm. 2020 Dec 11;37(1):28-32. doi: 10.1002/joa3.12466. eCollection 2021 Feb.
The need for pre- or peri-procedural imaging to rule out the presence of left atrial thrombus in patients undergoing catheter ablation of atrial fibrillation (AF) is unclear in the era of uninterrupted direct oral anticoagulant (DOAC) regimen. We sought to examine the safety of catheter ablation in appropriately selected patients with paroxysmal AF without performing screening for left atrial thrombus.
Consecutive patients planned for radiofrequency AF catheter ablation between January 2016 and June 2020 were enrolled, and prospectively studied. All subjects were receiving uninterrupted anticoagulation with DOACs for at least 4 weeks before the procedure. All subjects were in sinus rhythm the day of the procedure. The primary outcome of the study was ischemic stroke or transient ischemic attack (TIA) during at 30 days.
A total of 451 patients (age 59.7 ± 10.2 years, 289 males) with paroxysmal AF were included in the study. The mean CHADS-VASc score was 1.4 ± 1.2. The mean left ventricular ejection fraction and left atrial diameter were 60 ± 5% and 39.3 ± 4 mm, respectively. Regarding the anticoagulation regimen, apixaban was used in 197 (43.6%) patients, rivaroxaban in 148 (32.8%) patients, and dabigatran in 106 (23.5%) patients. None of the patients developed clinical ischemic stroke or TIA during the 30-day post-discharged period.
Catheter ablation can be safely performed in low-risk patients with paroxysmal AF without imaging for the detection of left atrial thrombus in the era of uninterrupted DOAC anticoagulation.
在不间断直接口服抗凝剂(DOAC)治疗方案的时代,对于接受房颤(AF)导管消融的患者,术前或术中成像以排除左心房血栓存在的必要性尚不清楚。我们试图研究在适当选择的阵发性房颤患者中不进行左心房血栓筛查而行导管消融的安全性。
纳入2016年1月至2020年6月计划进行射频房颤导管消融的连续患者,并进行前瞻性研究。所有受试者在手术前至少4周接受DOAC不间断抗凝治疗。手术当天所有受试者均为窦性心律。研究的主要结局是术后30天内发生缺血性卒中或短暂性脑缺血发作(TIA)。
共纳入451例阵发性房颤患者(年龄59.7±10.2岁,男性289例)。平均CHADS-VASc评分为1.4±1.2。平均左心室射血分数和左心房直径分别为60±5%和39.3±4mm。关于抗凝方案,197例(43.6%)患者使用阿哌沙班,148例(32.8%)患者使用利伐沙班,106例(23.5%)患者使用达比加群。在出院后30天内,无一例患者发生临床缺血性卒中或TIA。
在不间断DOAC抗凝治疗时代,对于低风险阵发性房颤患者,不进行左心房血栓检测成像也可安全地进行导管消融。